Strategies for treating idiopathic pulmonary fibrosis

被引：206

作者：

du Bois, R. M. ^{[1
]}

机构：

[1] Natl Jewish Hlth, Denver, CO 80206 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2010年 / 9卷 / 02期

关键词：

PLACEBO-CONTROLLED TRIAL; ENDOPLASMIC-RETICULUM STRESS; GENE-EXPRESSION PROFILES; LOW-DOSE PREDNISOLONE; INTERFERON GAMMA-1B; DOUBLE-BLIND; GASTROESOPHAGEAL-REFLUX; CXC CHEMOKINES; NOX ENZYMES; CYCLOPHOSPHAMIDE;

D O I：

10.1038/nrd2958

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Idiopathic pulmonary fibrosis (IPF) is the most common and most lethal diffuse fibrosing lung disease, with a mortality rate that exceeds that of many cancers. Recently, there have been many clinical trials of novel therapies for IPF. The results have mostly been disappointing, although two treatment approaches have shown some efficacy. This Review describes the difficulties of treating IPF and the approaches that have been tried or are in development, and concludes with suggestions of future therapeutic targets and strategies.

引用

页码：129 / 140

页数：12

共 76 条

[1] Short telomeres are a risk factor for idiopathic pulmonary fibrosis
Alder, Jonathan K.
Chen, Julian J. -L.
Lancaster, Lisa
Danoff, Sonye
Su, Shu-Chih
Cogan, Joy D.
Vulto, Irma
Xie, Mingyi
Qi, Xiaodong
Tuder, Rubin M.
Phillips, John A., III
Lansdorp, Peter M.
Loyd, James E.
Armanios, Mary Y.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (35) : 13051 - 13056
[2] [Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00
[3] Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis
Antoniou, K. M.
Nicholson, A. G.
Dimadi, M.
Malagari, K.
Latsi, P.
Rapti, A.
Tzanakis, N.
Trigidou, R.
Polychronopoulos, V.
Bouros, D.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (03) : 496 - 504
[4] Telomerase mutations in families with idiopathic pulmonary fibrosis
Armanios, Mary Y.
Chen, Julian J. -L.
Cogan, Joy D.
Alder, Jonathan K.
Ingersoll, Roxann G.
Markin, Cheryl
Lawson, William E.
Xie, Mingyi
Vulto, Irma
Phillips, John A., III
Lansdorp, Peter M.
Greider, Carol W.
Loyd, James E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (13) : 1317 - 1326
[5] Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Azuma, A
Nukiwa, T
Tsuboi, E
Suga, M
Abe, S
Nakata, K
Taguchi, Y
Nagai, S
Itoh, H
Ohi, M
Sato, A
Kudoh, S
Raghu, G
[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) : 1040 - 1047
[6] The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response
Basseri, Sana
Lhotak, Sarka
Sharma, Arya M.
Austin, Richard C.
[J]. JOURNAL OF LIPID RESEARCH, 2009, 50 (12) : 2486 - 2501
[7] The role of the Th2CC chemokine ligand CCL17 in pulmonary fibrosis
Belperio, JA
Dy, M
Murray, L
Burdick, MD
Xue, YY
Strieter, RM
Keane, MP
[J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (07) : 4692 - 4698
[8] Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)
Boon, Kathy
Bailey, Nathaniel W.
Yang, Jun
Steel, Mark P.
Groshong, Steve
Kervitsky, Dolly
Brown, Kevin K.
Schwarz, Marvin I.
Schwartz, David A.
[J]. PLOS ONE, 2009, 4 (04):
[9] Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?
Chambers, R. C.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 : S367 - S378
[10] Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis
Chaudhary, N. I.
Roth, G. J.
Hilberg, F.
Mueller-Ouernheim, J.
Prasse, A.
Zissel, G.
Schnapp, A.
Park, J. E.
[J]. EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) : 976 - 985

← 1 2 3 4 5 6 7 8 →